奥西默替尼
医学
肿瘤科
肺癌
化疗
内科学
铂金
队列
突变体
癌症
表皮生长因子受体
基因
埃罗替尼
生物化学
催化作用
化学
作者
Benjamin Besse,Kōichi Goto,Yongsheng Wang,Se‐Hoon Lee,Melina E. Marmarelis,Yuichiro Ohe,Reyes Bernabé,Dong‐Wan Kim,Jong-Seok Lee,Sophie Cousin,Eiki Ichihara,Yongsheng Li,Luis Paz‐Ares,Akira Ono,Rachel E. Sanborn,Naohiro Watanabe,Maria J. de Miguel,Carole Hélissey,Catherine A. Shu,Alexander I. Spira
标识
DOI：10.1016/j.jtho.2024.12.029
摘要
For patients with limited treatment options, amivantamab plus lazertinib demonstrated an antitumor activity with a safety profile characterized by EGFR- or MET-related adverse events, which were generally manageable.
科研通智能强力驱动
Strongly Powered by AbleSci AI
PDF的下载单位、IP信息已删除
(2025-6-4)
cdercder
AllRightReserved
dde
无极微光
GingerF
Twonej
wanci
juwairen119
sagitar
Scorpia112
TYK
CR7
嘻嘻哈哈
殷勤的紫槐
HFH
sy
唠叨的轩轩
liuzhuohao
eric888
畔畔
皖公网安备34019202002308
